Liver fibrosis has remained challenging to treat using RNA therapies due to a lack of delivery systems for targeting activated liver-resident cells called fibroblasts. Both the solid fibroblast structure and the lack of specificity or affinity to target these fibroblasts have impeded current lipid nanoparticles from entering activated liver-resident fibroblasts, and thus they are unable to deliver RNA therapeutics. Now, researchers at the University of Pennsylvania have found a new way to synthesize ligand-tethered lipid nanoparticles, increasing their selectivity and allowing them to target liver fibroblasts.
An official website of the United States government.